Gilead Sciences, Inc.
NEWS
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 27, 2020.
Gilead Sciences filed a lawsuit against the United States government alleging the U.S. Centers for Disease Control and Prevention violated a contract that governed an HIV research collaboration between the company and government agency.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 24, 2020.
Shares of Gilead Sciences fell after reports suggest remdesivir failed to distinguish itself as a treatment for COVID-19 in a clinical study conducted in China. But, there are some questions about the veracity of the study.
The goal is to support the discovery and development of next-generation drug and engineered cell therapies, specifically with a focus on natural killer (NK) cells.
BioSpace takes an in-depth look at the human immunodeficiency virus including research, drugs in the pipeline and treatments. Check out the free downloadable report.
There’s plenty of news related to clinical trials related to COVID-19, but it does seem to be drowning out non-COVID-19-related clinical trials. Here’s a look.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 17, 2020.
Although not official and largely anecdotal, there are early signs that Gilead’s experimental antiviral drug, remdesivir, is effective in treating COVID-19.
JOBS
IN THE PRESS